<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533232</url>
  </required_header>
  <id_info>
    <org_study_id>PILL-MAC-001</org_study_id>
    <nct_id>NCT02533232</nct_id>
  </id_info>
  <brief_title>Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia</brief_title>
  <official_title>Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a randomized double-blind placebo controlled trial which aims to determine the
      beneficial effects of minocycline augmentation to clozapine in partial responders to
      Treatment Resistant Schizophrenia (TRS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine if the addition of minocycline to Clozapine, Treatment
      as Usual (TAU) Improves negative symptoms and/or positive symptoms.

      The secondary objectives are to determine:

        -  Effects on cognitive functioning.

        -  Effects on social functioning and quality of life.

        -  Safety and tolerability.

        -  Possible additive effects of Minocycline added to TAU

        -  The effect on inflammatory biomarkers associated with schizophrenia. Both pro and
           anti-inflammatory cytokines will be drawn at baseline and endpoint. We will test to see
           if minocycline is associated with improvements in abnormal cytokines as compared to
           placebo.

      The study will be a randomized double-blind placebo controlled trial of minocycline added to
      clozapine (Treatment as Usual) in TRS. There will be two treatment arms: one arm receiving
      TAU with minocycline and the other TAU with placebo for a period of twelve weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale PANSS</measure>
    <time_frame>3 months</time_frame>
    <description>PANSS is an assessment measures to assess severity of symptoms of schizophrenia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CogState</measure>
    <time_frame>3 Month</time_frame>
    <description>Measuring all seven domains recommended by MATRICS (NIMH initiative). These domains include speed processing, attention/vigilance, Working memory (nonverbal &amp; verbal), verbal learning, visual learning, reasoning and problem solving and social cognition's.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Social Functioning Scale</measure>
    <time_frame>3 Month</time_frame>
    <description>Self-rating questionnaire assessing social functioning in 7 domains.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorder</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for Minocycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline 200mg once a day orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline 200mg per day</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Mesodrum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged between 18-65 years, IQ &gt;70 (to complete assessments)
             identified by treating psychiatrist.

          -  Confirmation of schizophrenia by using The MINI psychiatric interview (at baseline
             only)

          -  Assessed as competent to provide informed consent by treating psychiatrist.

          -  Antipsychotic medication has remained stable 4 weeks prior to baseline *. Assessed as
             a partial responder to clozapine: patients prescribed clozapine at a stable
             therapeutic dose for a minimum of 3 months with total Positive and Negative Syndrome
             Schizophrenia (PANSS) score &gt;70.

        Exclusion Criteria:

          -  Prior history of intolerance or serious side effects (hepatotoxicity,
             photosensitivity, blood dyscrasias) to any of the Tetracyclines.

          -  Concomitant Penicillin therapy or concomitant anticoagulant therapy.

          -  Active substance abuse (except nicotine or caffeine) or dependence within the last
             three months according to ICD 10 criteria.

          -  Treatment with Warfarin or Lamotrigine.

          -  Current or previous treatment with minocycline or other tetracycline antibiotics in
             the preceding three months before study entry.

          -  Relevant current or past hematologic, hepatic, renal, neurological or other medical
             disorder that in the opinion of the principal investigator may interfere with the
             study.

          -  Pregnant or breast-feeding females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Inti Qurashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester University ,UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr.Inti Qurashi, MD</last_name>
    <email>Inti.Qurashi@merseycare.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof.Imran B Chaudhry, MD</last_name>
    <email>ibchaudhry@btinternet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abasi Shaheed Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Munir Hamarani, FCPS</last_name>
      <phone>00923009272002</phone>
      <email>mmham@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Prof Munir Hamarani, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Civil hospital Karachi</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Raza U Rahman, FCPS</last_name>
      <phone>00-92-21-9215740-50</phone>
      <phone_ext>2500</phone_ext>
      <email>razaur@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Prof Raza U Rahman, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karwn e Hayat</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ajmal Kazmi, MRCPsych</last_name>
      <phone>00923213783890</phone>
      <email>kazmiajmal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr Ajmal Kazmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Behavioral Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shehla Ahmed</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://pill.org.pk</url>
    <description>Website of Pakistan Institute of Learning and Living</description>
  </link>
  <reference>
    <citation>Qurashi I, Collins JD, Chaudhry IB, Husain N. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. J Psychopharmacol. 2014 Jul;28(7):707-8. doi: 10.1177/0269881114527358. Epub 2014 Mar 19.</citation>
    <PMID>24646811</PMID>
  </reference>
  <reference>
    <citation>Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23(4):663-74. Review.</citation>
    <PMID>9366002</PMID>
  </reference>
  <reference>
    <citation>Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001 Apr;158(4):518-26.</citation>
    <PMID>11282684</PMID>
  </reference>
  <reference>
    <citation>Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409. Review.</citation>
    <PMID>15925493</PMID>
  </reference>
  <reference>
    <citation>Sommer IE, Begemann MJ, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012 Sep;38(5):1003-11. doi: 10.1093/schbul/sbr004. Epub 2011 Mar 21. Review.</citation>
    <PMID>21422107</PMID>
  </reference>
  <reference>
    <citation>Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpé S, Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res. 1998 Jun 22;32(1):9-15.</citation>
    <PMID>9690329</PMID>
  </reference>
  <reference>
    <citation>van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008 Nov 1;64(9):820-2. doi: 10.1016/j.biopsych.2008.04.025. Epub 2008 Jun 4.</citation>
    <PMID>18534557</PMID>
  </reference>
  <reference>
    <citation>Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci. 2003 Nov;1003:119-30. Review.</citation>
    <PMID>14684440</PMID>
  </reference>
  <reference>
    <citation>Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991 Oct;148(10):1301-8. Review.</citation>
    <PMID>1654746</PMID>
  </reference>
  <reference>
    <citation>Labrie V, Roder JC. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18. Review.</citation>
    <PMID>19695284</PMID>
  </reference>
  <reference>
    <citation>Anticevic A, Gancsos M, Murray JD, Repovs G, Driesen NR, Ennis DJ, Niciu MJ, Morgan PT, Surti TS, Bloch MH, Ramani R, Smith MA, Wang XJ, Krystal JH, Corlett PR. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16720-5. doi: 10.1073/pnas.1208494109. Epub 2012 Sep 25.</citation>
    <PMID>23012427</PMID>
  </reference>
  <reference>
    <citation>Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008 Feb;65(2):154-64. doi: 10.1001/archgenpsychiatry.2007.37.</citation>
    <PMID>18250253</PMID>
  </reference>
  <reference>
    <citation>Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. Curr Med Res Opin. 1997;14(1):1-20. Review.</citation>
    <PMID>9524789</PMID>
  </reference>
  <reference>
    <citation>Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004 Dec;25(12):609-12. Review.</citation>
    <PMID>15530637</PMID>
  </reference>
  <reference>
    <citation>Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001 Apr 15;21(8):2580-8.</citation>
    <PMID>11306611</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Anti-inflammatory</keyword>
  <keyword>Clozapine</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Psychosis NOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

